Abbott Careers
Contact
Overview
Daclizumab
Elotuzumab (HuLuc63)
TRU-016
Volociximab (M200)
PDL192
Phase 3 Study in Multiple Sclerosis
Proposed Mechanism of Action
|
|
Abbott Investor Relations Abbott Careers Contact |
|
|||||||||||||
|
|
|||||||||||||||
Overview Daclizumab Elotuzumab (HuLuc63) TRU-016 Volociximab (M200) PDL192 |
|
Phase 3 Study in Multiple Sclerosis Proposed Mechanism of Action
|
|||||||||||||